Statins can cause real side effects in some people, ranging from muscle pain to a modest increase in diabetes risk, but the actual rates of serious harm are lower than many people assume. Understanding the specific risks, how common they are, and who faces the greatest chance of problems can help you weigh the trade-offs clearly.
Muscle Pain Is the Most Common Complaint
Muscle symptoms are the number one reason people stop taking statins. The experience can range from general achiness and stiffness to weakness, cramping, and fatigue that interferes with daily activity. These symptoms typically affect the large muscle groups: thighs, calves, back, and shoulders.
How common the problem truly is, though, is more complicated than it seems. In clinical trials where patients didn’t know whether they were taking a statin or a sugar pill, the difference in muscle complaints between the two groups was small, around 1.26% for statin users versus 1.00% for placebo. One large trial of atorvastatin found virtually identical rates: 2.03% on the drug versus 2.00% on placebo. That gap is surprisingly narrow.
Yet in open-label settings where people know they’re taking a statin, reported muscle problems jump dramatically. One study found that 43% of patients with a history of muscle side effects reported symptoms on a statin, but 27% also reported them on placebo. Researchers estimate that 30 to 50% of people who believe their muscle pain is caused by a statin may actually have another source. This doesn’t mean statin-related muscle pain isn’t real. It is. But the nocebo effect, where expecting a side effect makes you more likely to experience it, plays a significant role.
When statins do cause genuine muscle problems, the likely mechanism involves mitochondria, the energy-producing structures inside muscle cells. Statin use can increase the production of damaging molecules called reactive oxygen species, reducing the muscle’s ability to generate energy. In animal studies, one commonly prescribed statin decreased maximal energy output in muscle cells by 39%. People who develop muscle symptoms on statins show distinct patterns of reduced energy-related gene activity in their skeletal muscle compared to people who tolerate the drugs well.
Rhabdomyolysis: A Rare but Serious Risk
The most feared muscle-related side effect is rhabdomyolysis, a condition where muscle tissue breaks down rapidly and releases proteins into the bloodstream that can damage the kidneys. This is genuinely dangerous and can require hospitalization. The good news is that it’s very uncommon: current estimates place the incidence at 0.6 to 1.2 cases per 10,000 people per year. That translates to roughly 1 in 10,000 statin users annually. The risk rises when statins are combined with certain other medications that slow the drug’s breakdown in the body.
Statins Can Push Blood Sugar Higher
Statins increase the risk of developing type 2 diabetes, and this effect is dose-dependent. A 2024 meta-analysis published in The Lancet found that low-to-moderate dose statin therapy raised new diabetes diagnoses by about 10%, while high-intensity therapy increased the risk by 36%.
This doesn’t mean statins cause diabetes out of nowhere. About 62% of new diabetes cases in these trials occurred in people whose blood sugar was already near the diagnostic threshold before they started the medication. In other words, statins appear to tip people who are already on the edge of diabetes over the line sooner than they would have crossed it on their own. If your blood sugar is well within normal range, your personal risk of statin-induced diabetes is considerably lower.
Concerns About Memory and Thinking
In 2012, the FDA added a warning to all statin labels about possible cognitive effects, including memory loss, confusion, and amnesia. This warning was based on post-marketing reports from patients rather than on findings from controlled clinical trials. The reports described symptoms that were generally reversible, resolving after the statin was stopped.
The picture is complicated because cholesterol plays a role in brain cell membranes and nerve signaling, which gives the concern biological plausibility. However, large clinical trials have not consistently shown that statins impair cognition across broad populations. Some people do report a noticeable mental fog while on the drugs. If you experience confusion or memory problems after starting a statin, it’s worth discussing with your prescriber, since the symptoms typically resolve with discontinuation or a switch to a different statin.
A Small Increase in Hemorrhagic Stroke Risk
While statins reduce the overall risk of stroke (by about 22% in primary prevention trials), they appear to slightly increase the risk of one specific type: hemorrhagic stroke, which involves bleeding in the brain rather than a clot. A meta-analysis of 33 trials covering more than 216,000 people found the risk of hemorrhagic stroke was 17% higher in statin users overall.
Certain groups face a larger increase. People who have already had a stroke or a transient ischemic attack (a “mini-stroke”) saw a 46% higher risk of hemorrhagic stroke on statin therapy. People aged 65 and older had a 34% higher risk. For most statin users who have never had a stroke, the absolute risk of this event remains very small, and the reduction in clot-based strokes more than offsets it. But for someone with a history of brain bleeding, this trade-off deserves careful consideration.
Drug and Food Interactions
Several statins are broken down in the liver by the same enzyme pathway, and anything that blocks that pathway can cause statin levels to build up in your blood, increasing the chance of muscle damage and other side effects. Grapefruit juice is the most widely known culprit, but the list of interacting substances is long. It includes certain antibiotics (clarithromycin, erythromycin), antifungal medications, some blood pressure drugs (diltiazem, verapamil, amlodipine), the heart rhythm drug amiodarone, HIV protease inhibitors, and immunosuppressants like cyclosporine.
Not all statins are affected equally. The interactions are most relevant for three specific statins that rely heavily on that liver enzyme pathway. If you take multiple medications, your pharmacist or prescriber can check for conflicts and potentially switch you to a statin that uses a different metabolic route.
Liver Damage Fears Are Largely Outdated
For years, people on statins were told to get regular blood tests checking liver enzymes, which created the impression that statins routinely harm the liver. The FDA dropped its recommendation for routine liver monitoring back in 2012, and the most recent cardiology guidelines (2026) confirm that routine liver enzyme testing on statin therapy is unnecessary. Liver testing is now recommended only if you develop specific symptoms like yellowing of the skin, unexplained fatigue, itching, nausea, or abdominal pain. Clinically significant liver injury from statins is rare.
CoQ10 May Help With Muscle Symptoms
Statins reduce the body’s production of coenzyme Q10, a molecule involved in cellular energy production, by an estimated 16 to 54%. This depletion is one proposed explanation for why statins cause muscle problems. A meta-analysis of 12 randomized trials found that CoQ10 supplements significantly reduced statin-related muscle pain, weakness, cramping, and tiredness compared to placebo. The improvements were consistent and statistically meaningful across all four symptom types.
Interestingly, CoQ10 didn’t change blood levels of creatine kinase, a marker of muscle cell damage, which suggests the supplement works on symptom perception or a pathway that blood tests don’t capture. CoQ10 supplementation is considered safe, and while it doesn’t work for everyone, it’s a reasonable option to try before giving up on statin therapy entirely.
Putting the Risks in Context
The side effects are real, but so are the benefits. In primary prevention (people who haven’t yet had a heart attack or stroke), statins reduce the risk of heart attack by about 33%, stroke by 22%, and composite cardiovascular events by 28%. They also reduce the risk of dying from any cause by 8%. In absolute terms, for every 1,000 people treated, roughly 9 fewer will have a heart attack and about 4 fewer will have a stroke over the trial period.
For people with established heart disease, the benefits are larger. For people at low cardiovascular risk, the benefits are smaller, and the side effects carry proportionally more weight in the decision. The question isn’t really whether statins are “bad” in a blanket sense. It’s whether the specific risks matter more or less than the specific benefits for your individual situation, your cardiovascular risk level, your age, and your tolerance for the drug’s effects on your daily life.